MedPath

Portal Therapeutics, Inc.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:0
Completed:0

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic Protoporphyria

Phase 2
Conditions
Erythropoietic Protoporphyria (EPP)
Interventions
Drug: Placebo
First Posted Date
2025-05-14
Last Posted Date
2025-05-14
Lead Sponsor
Portal Therapeutics, Inc.
Target Recruit Count
14
Registration Number
NCT06971900
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants

Phase 1
Recruiting
Conditions
Healthy Adult Participants
Interventions
Drug: Placebo
First Posted Date
2024-04-04
Last Posted Date
2025-04-04
Lead Sponsor
Portal Therapeutics, Inc.
Target Recruit Count
108
Registration Number
NCT06346509
Locations
🇺🇸

Celerion, Tempe, Arizona, United States

News

No news found
© Copyright 2025. All Rights Reserved by MedPath